A randomised study of dabigatran in elective percutaneous coronary intervention in stable coronary artery disease patients
EuroIntervention 2013;8:1052-1060 published online ahead of print November 2012. DOI: 10.4244/EIJV8I9A162
Pascal Vranckx1,2, MD; Freek W.A. Verheugt3, MD, PhD; Moniek P. de Maat4, PhD; Victor A.W.M. Ulmans5, MD; Evelyn Regar6, MD, PhD; Peter Smits7, MD, PhD; Jurrien M. ten Berg8, MD, PhD; Wietze Lindeboom2, BSc; Russel L. Jones9, MSc; Jeffrey Friedman10, MD; Paul Reilly10, PhD; Frank W.G. Leebeek4*, MD, PhD
1. Department of Cardiac Intensive Care & Interventional Cardiology, Hartcentrum, Hasselt, Belgium; 2. Cardialysis, Clinical Research Management & Core Laboratories, Rotterdam, The Netherlands; 3. Department of Cardiology, Onze Lieve
Aims: Patients receiving long-term anticoagulant treatment with dabigatran may need to undergo a percutaneous coronary intervention (PCI